Europe — EMA

Nuvaxovid Jn.1

Matrix M, the active ingredient in Nuvaxovid Jn.1, the active ingredient in Nuvaxovid Jn.1, is a vaccine presented as a for intramuscular use.

Matrix M, Sars-Cov-2, Variant Omicron Jn.1, Spike Protein, Recombinant, Expressed In Sf9 Cells Deriv

Request sourcing

Pack/s

What is Matrix M, Sars-Cov-2, Variant Omicron Jn.1, Spike Protein, Recombinant, Expressed In Sf9 Cells Deriv?

Matrix M, the active ingredient in Nuvaxovid Jn.1, the active ingredient in Nuvaxovid Jn.1, is a vaccine presented as a for intramuscular use. It targets the SARS‑CoV‑2 Omicron Jn.1 variant and is intended for prophylactic immunisation in adults.

GNH USA supplies Nuvaxovid Jn.1 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

What is Matrix M, Sars-Cov-2, Variant Omicron Jn.1, Spike Protein, Recombinant, Expressed In Sf9 Cells Deriv used for?

Nuvaxovid Jn.1 is a recombinant vaccine that acts on the immune system of the SARS‑CoV‑2 Omicron Jn 1 variant . - COVID‑19 : Pre‑ pre‑ pre‑ pre

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →